pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial
Boehringer Ingelheim
Boehringer Ingelheim clinical programs — 62 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
- Employees
- 46,699
- Programs
- 193
- Drugs
- 113
- Patents
- 25
Boehringer Ingelheim projects
62 ClinicalTrials.gov programs sponsored by Boehringer Ingelheim.
Boehringer Ingelheim has 62 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
dabigatran etexilate
Boehringer Ingelheim
Venous Thromboembolism
1 trial -
fixed dose combination of telmisartan+amlodipine
Boehringer Ingelheim
Hypertension
1 trial -
linagliptine 5 mg
Boehringer Ingelheim
Diabetes Mellitus, Type 2
1 trial -
obrixtamig
Boehringer Ingelheim
Small Cell Lung Cancer (SCLC)
1 trial -
placebo
Boehringer Ingelheim
Pulmonary Fibrosis
1 trial -
placebo plus docetaxel
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
1 trial -
survodutide
Boehringer Ingelheim
Obesity
1 trial -
telmisartan/amlodipine 40/5 mg fixed combination
Boehringer Ingelheim
Hypertension
1 trial -
tiotropium
Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
1 trial -
tiotropium + olodaterol
Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
1 trial -
tiotropium 5mcg/day
Boehringer Ingelheim
Asthma
1 trial -
tiotropium high dose
Boehringer Ingelheim
Asthma
1 trial -
warfarin
Boehringer Ingelheim
Atrial Fibrillation
1 trial -
zongertinib
Boehringer Ingelheim
Lung Cancer, Non-squamous, Non-small Cell
1 trial
Frequently asked questions
How many clinical projects does Boehringer Ingelheim have?
62 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.